LRP5 and neoplasm: Collectively, these findings demonstrate that LRP5-overexpressing osteocyte-derived CM exerts its anti-tumor effects on EO771 cells primarily through the LIMA1–MYO5B signaling axis, with LIMA1 acting functionally via MYO5B.